Please login to the form below

Not currently logged in
Email:
Password:

FDA approves drug for drooling

The US Food and Drug Administration has approved Shionogi Pharma's Cuvposa oral solution to treat chronic severe drooling in children

The US Food and Drug Administration (FDA) has approved Shionogi Pharma's Cuvposa (glycopyrrolate) oral solution to treat chronic severe drooling in children who suffer from neuromuscular dysfunction related to neurologic disorders. The drug is cleared for children aged three years to 16 years.

Glycopyrrolate, which was cleared for US marketing decades ago in tablet form as a treatment for peptic ulcers, was already frequently used off-label for the paediatric drooling indication, as it lowers the volume of saliva produced in the mouth.

The new approval is the result of a 2001 advisory committee meeting convened by the FDA "to discuss how best to develop products for drooling with ethically and scientifically sound trials in children who have neurological disorders," the agency said.

Cuvposa is a flavoured oral solution designed for ease of use in paediatric patients. When the drug was used off-label, the tablets had to be crushed and mixed with fluid, which was unpalatable to some children and also often resulted in inexact dosing.

Clinical trials of Cuvposa showed that 78 per cent of the children taking the active drug had clinical improvement in drooling, versus 19 per cent of the placebo group.

29th July 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical website. Support the...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....